Protein-Engineered Radiometal Chelates for Immunotherapy of Breast Cancer
Abstract
The objective of this project is to genetically engineer a radiometal binding site in a human antibody constant region, for eventual use in tumor radioimmunotherapy. Our initial design was based on molecular modeling and used a humanized antibody Fab fragment expressed in E. coli. The engineered binding site, consisting of 5 point mutations in the human Ck domain, destabilized the recombinant protein, leading to proteolysis. We have attempted to address this problem by using expedited isolation procedures, modifying the binding site design, and expressing the protein within protease-negative host strains.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 1998
- Accession Number
- ADA360809
Entities
People
- Jefferson Foote